147 related articles for article (PubMed ID: 23296123)
1. Immunotherapy in new pre-clinical models of HPV-associated oral cancers.
Paolini F; Massa S; Manni I; Franconi R; Venuti A
Hum Vaccin Immunother; 2013 Mar; 9(3):534-43. PubMed ID: 23296123
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors.
Domingos-Pereira S; Galliverti G; Hanahan D; Nardelli-Haefliger D
J Immunother Cancer; 2019 May; 7(1):122. PubMed ID: 31060612
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models.
Venuti A; Curzio G; Mariani L; Paolini F
Cancer Immunol Immunother; 2015 Oct; 64(10):1329-38. PubMed ID: 26138695
[TBL] [Abstract][Full Text] [Related]
4. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
5. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV
Dorta-Estremera S; Chin RL; Sierra G; Nicholas C; Yanamandra AV; Nookala SMK; Yang G; Singh S; Curran MA; Sastry KJ
Cancer Res; 2018 Sep; 78(18):5327-5339. PubMed ID: 30054333
[TBL] [Abstract][Full Text] [Related]
6. Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16
Lin YH; Yang MC; Tseng SH; Jiang R; Yang A; Farmer E; Peng S; Henkle T; Chang YN; Hung CF; Wu TC
Cancer Immunol Res; 2018 Mar; 6(3):305-319. PubMed ID: 29362220
[TBL] [Abstract][Full Text] [Related]
7. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
[TBL] [Abstract][Full Text] [Related]
8. A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers.
Radaelli A; De Giuli Morghen C; Zanotto C; Pacchioni S; Bissa M; Franconi R; Massa S; Paolini F; Muller A; Venuti A
Virus Res; 2012 Dec; 170(1-2):44-52. PubMed ID: 22951311
[TBL] [Abstract][Full Text] [Related]
9. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors.
Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G
Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
12. Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model.
Cerutti ML; Alonso LG; Tatti S; de Prat-Gay G
Int J Cancer; 2012 Apr; 130(8):1813-20. PubMed ID: 21780110
[TBL] [Abstract][Full Text] [Related]
13. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.
Sewell DA; Douven D; Pan ZK; Rodriguez A; Paterson Y
Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):92-7. PubMed ID: 14732776
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
[TBL] [Abstract][Full Text] [Related]
15. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
16. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
[TBL] [Abstract][Full Text] [Related]
17. Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.
Jindra C; Huber B; Shafti-Keramat S; Wolschek M; Ferko B; Muster T; Brandt S; Kirnbauer R
PLoS One; 2015; 10(9):e0138722. PubMed ID: 26381401
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model.
Domingos-Pereira S; Roh V; Hiou-Feige A; Galliverti G; Simon C; Tolstonog GV; Nardelli-Haefliger D
Oncoimmunology; 2021 Apr; 10(1):1912473. PubMed ID: 33907631
[TBL] [Abstract][Full Text] [Related]
19. HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy.
Paolini F; Curzio G; Cordeiro MN; Massa S; Mariani L; Pimpinelli F; de Freitas AC; Franconi R; Venuti A
Hum Vaccin Immunother; 2017 Feb; 13(2):291-297. PubMed ID: 27929754
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
